CAS 1651165-06-8 | BASI-009 : Basimglurant Sulfate
(World's Largest Pharmaceutical Supplier)

CAS 1651165-06-8 is a chemical compound with the molecular formula C18H23NO3. It is also known by its trade name, BMS-986177. This compound is a potent and selective antagonist of the sphingosine-1-phosphate receptor subtype 1 (S1P1). It has been developed as a potential treatment for autoimmune diseases such as multiple sclerosis and inflammatory bowel disease.

Properties of CAS 1651165-06-8:

- Molecular weight: 305.38 g/mol

- Melting point: Not available

- Boiling point: Not available

- Solubility: Soluble in DMSO and methanol

- Appearance: Off-white to yellow solid

CAS 1651165-06-8 has been shown to be highly selective for the S1P1 receptor subtype, with minimal activity against other S1P receptor subtypes. This selectivity is important because non-selective S1P receptor antagonists can cause unwanted side effects such as bradycardia, hypertension, and macular edema.

In preclinical studies, CAS 1651165-06-8 has demonstrated efficacy in reducing disease activity in animal models of multiple sclerosis and inflammatory bowel disease. These results have led to the initiation of clinical trials to evaluate the safety and efficacy of this compound in humans.

In a phase 1 clinical trial, CAS 1651165-06-8 was well-tolerated and demonstrated dose-dependent pharmacodynamic effects on lymphocyte counts, consistent with S1P1 receptor antagonism. Phase 2 clinical trials are currently underway to evaluate the efficacy of this compound in treating multiple sclerosis and inflammatory bowel disease.

In conclusion, CAS 1651165-06-8 is a selective S1P1 receptor antagonist with potential therapeutic applications in autoimmune diseases. Its selectivity for the S1P1 receptor subtype may reduce the risk of unwanted side effects commonly associated with non-selective S1P receptor antagonists. Clinical trials are ongoing to evaluate the safety and efficacy of this compound in humans.